Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of Mexiletine (Namuscla) in Paediatric Myotonic Disorders
2024-513484-89-00Phase 4Completed
- Sponsor
- Lupin Limited
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fresolimumab in non-dystrophic myotonia (NDM), myotonic dystrophy type 1 (DM1), myotonic dystrophy type 2 (DM2) and 1 more, sponsored by Lupin Limited. Primary endpoints: Number and frequency of adverse events and serious adverse events, Incidence of adverse events of special interest and 2 more. Started Nov 2024; status: completed.
02
Drugs
fresolimumab
03
Conditions
non-dystrophic myotonia (NDM)myotonic dystrophy type 1 (DM1)myotonic dystrophy type 2 (DM2)myotonic disorders
Beyond the preview
Go deeper on 2024-513484-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513484-89-00.